DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Afinitor (Everolimus) - Current Clinical Trials


Afinitor Related Clinical Trials

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer [Recruiting]

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) [Completed]

Dose Finding Study of RAD001 (Everolimus, Afinitor´┐Ż) in Combination With BEZ235 in Patients With Advanced Solid Tumors [Completed]

Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression [Not yet recruiting]

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer [Recruiting]

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease [Withdrawn]

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer [Active, not recruiting]

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients [Recruiting]

Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab [Recruiting]

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients [Active, not recruiting]

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects [Completed]

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma [Terminated]

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients [Completed]

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas [Terminated]

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib [Completed]

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma [Recruiting]

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer [Terminated]

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) [Recruiting]

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI [Recruiting]

Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma [Recruiting]

Anakinra or Denosumab and Everolimus in Advanced Cancer [Recruiting]

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer [Recruiting]

Sirolimus for Autoimmune Disease of Blood Cells [Recruiting]

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC [Terminated]

Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas [Active, not recruiting]

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer [Completed]

Topical Rapamycin to Erase Angiofibromas in TSC [Completed]

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas [Recruiting]

Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients [Completed]

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) [Active, not recruiting]

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer [Completed]

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma [Recruiting]

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma [Withdrawn]

Safety of Everolimus and Pemetrexed in Lung Cancer Patients [Completed]

Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer [Withdrawn]

Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) [Not yet recruiting]

Vandetanib With Everolimus [Recruiting]

Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients [Withdrawn]

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor [Active, not recruiting]

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET [Completed]

Everolimus for Children With Recurrent or Progressive Ependymoma [Recruiting]

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients [Completed]

Pharmacokinetic of Everolimus and Atorvastatin Co-administration [Completed]

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer [Completed]

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects [Completed]

Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer [Not yet recruiting]

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma [Recruiting]

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia [Active, not recruiting]

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium [Active, not recruiting]

Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) [Completed]

A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors [Not yet recruiting]

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers [Active, not recruiting]

Rapamycin and Regulatory T Cells in Kidney Transplantation [Completed]

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer [Recruiting]

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma [Active, not recruiting]

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma [Recruiting]

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma [Completed]

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma [Active, not recruiting]

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer [Active, not recruiting]

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures [Active, not recruiting]

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers [Recruiting]

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma [Completed]

A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer [Recruiting]

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer [Active, not recruiting]

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas [Completed]

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis [Recruiting]

Exemestane-RAD001-Metformin [Active, not recruiting]

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome [Withdrawn]

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma [Completed]

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors [Active, not recruiting]

Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study [Recruiting]

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer [Terminated]

Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer [Withdrawn]

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas [Recruiting]

Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma [Completed]

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection [Completed]

Pharmacokinectics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity [Terminated]

RAD001 in Advanced Hepatocellular Carcinoma [Completed]

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer [Active, not recruiting]

Influence of Exceptional Patient Characteristics on Everolimus Exposure [Recruiting]

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors [Completed]

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors [Active, not recruiting]

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) [Recruiting]

Study of Temsirolimus, Topotecan, and Bortezomib [Completed]

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane [Terminated]

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors [Completed]

A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck [Terminated]

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma [Recruiting]

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer [Active, not recruiting]

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients [Active, not recruiting]

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors [Completed]

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. [Completed]

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) [Active, not recruiting]

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer [Recruiting]

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients [Active, not recruiting]

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer [Terminated]

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer [Completed]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017